Trials assessing parmacotherapeutic management of aggression in psychiatric patients: Comparability with clinical practice

Pharmacopsychiatry

Volumn 43, Issue 6, 2010, Pages 205-209

  Goedhard, L E ^a,b   Stolker, J J ^b,c   Nijman, H L I ^a,d   Egberts, T C G ^b,e   Heerdink, E R ^a,b,e,f  

^a Altrecht Mental Health Institute   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Arkin Mental Health Institute   (Netherlands)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; MOOD STABILIZER; NEUROLEPTIC AGENT;

AGGRESSION; AUTISM; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DEPRESSION; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MENTAL PATIENT; PERSONALITY DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; AGGRESSION; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PATIENT SELECTION; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 77956440627     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0030-1254091     Document Type: Review

References (45)

1. Allan ER, Alpert M, Sison CE, etal. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J Clin Psychiatry 1996 57 455-459
2. Alpert M, Allan ER, Citrome L, etal. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 1990 26 367-371
3. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996 16 38-44
4. Caldwell A. Hospital accountability: perceptions and costs. Front Health Serv Manage 1992 8 38-40
5. Caspi N, Modai I, Barak P, etal. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol 2001 16 111-115
6. Citrome L, Casey DE, Daniel DG, etal. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv 2004 55 290-294
7. Citrome L, Volavka J, Czobor P, etal. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001 52 1510-1514
8. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997 54 1081-1088
9. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995 15 243-249
10. Davidson JR, McLeod MN, Turnbull CD, etal. A comparison of phenelzine and imipramine in depressed inpatients. J Clin Psychiatry 1981 42 395-397
11. Davidson JR, Landerman LR, Farfel GM, etal. Characterizing the effects of sertraline in post-traumatic stress disorder. Psychol Med 2002 32 661-670
12. de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994 4 479-486
13. Dorrego MF, Canevaro L, Kuzis G, etal. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. J Neuropsychiatry Clin Neurosci 2002 14 289-295
14. Edlund MJ, Craig TJ, Richardson MA. Informed consent as a form of volunteer bias. Am J Psychiatry 1985 142 624-627
15. Fassino S, Leombruni P, Daga G, etal. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol 2002 12 453-459
16. Fava M, Nierenberg AA, Quitkin FM, etal. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull 1997 33 101-103
17. Frankenburg F, Zanarini M. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002 63 442-446
18. Goedhard LE, Stolker JJ, Heerdink ER, etal. Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review. J Clin Psychiatry 2006 67 1013-1024
19. Hollander E, Allen A, Lopez RP, etal. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001 62 199-203
20. Hollander E, Tracy KA, Swann AC, etal. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003 28 1186-1197
21. Hunter M, Carmel H. The cost of staff injuries from inpatient violence. Hospital and Community Psychiatry 1992 43 586-588
22. Jadad AR, Moore RA, Carroll D, etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 1-12
23. Lipman RS, Covi L, Rickels K, etal. Imipramine and chlordiazepoxide in depressive and anxiety disorders. I. Efficacy in depressed outpatients. Arch Gen Psychiatry 1986 43 68-77
24. Maoz G, Stein D, Meged S, etal. The antiaggressive action of combined haloperidol-propranolol treatment in schizophrenia. European Psychologist 2000 5 312-325
25. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997 58 538-546
26. Mattes JA. Comparative effectiveness of carbamazepine and propranolol for rage outbursts. J Neuropsychiatry Clin Neurosci 1990 2 159-164
27. McDougle CJ, Naylor ST, Cohen DJ, etal. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996 53 1001-1008
28. Min SK, Rhee CS, Kim CE, etal. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J 1993 34 179-190
29. Monnelly EP, Ciraulo DA, Knapp C, etal. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003 23 193-196
30. Nickel MK, Nickel C, Mitterlehner FO, etal. Treatment of aggression with topiramate in male borerline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005 57 495-499
31. Nijman H, Muris P, etal. The staff observation aggression scale Revised (SOAS-R). Aggress Behav 1999 25 197-209
32. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995 166 712-726; discussion 727-733
33. Ratey JJ, Sorgi P, O'Driscoll GA, etal. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992 53 41-46
34. Rinne T, van den Brink W, Wouters L, etal. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002 159 2048-2054
35. Salzman C, Wolfson AN, Schatzberg A, etal. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995 15 23-29
36. Soloff PH, George A, Nathan S, etal. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989 9 238-246
37. Soloff PH, George A, Nathan RS, etal. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986 43 691-697
38. Starfield B. Quality-of-care research: internal elegance and external relevance. JAMA 1998 280 1006-1008
39. Tlusta E, Handoko KB, Majoie M, etal. Clinical relevance of patients with epilepsy included in clinical trials. Epilepsia 2008 49 1479-1480
40. van der Kolk BA, Dreyfuss D, Michaels M, etal. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994 55 517-522
41. Vartiainen H, Tiihonen J, Putkonen A, etal. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995 91 348-351
42. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001 62 849-854
43. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004 65 903-907
44. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002 159 469-473
45. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D Report. Am J Psychiatry 2009 166 599-607